Status:
RECRUITING
Targeting Trimethylamine N-Oxide for Cardiovascular Health In Liver Transplant Recipients
Lead Sponsor:
Virginia Commonwealth University
Conditions:
Liver Transplant
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Despite medical and surgical advances, long-term survival in liver transplant (LT) recipients is compromised by an increased risk of cardiovascular disease (CVD) after transplant, the mechanisms of wh...
Detailed Description
Despite medical and surgical advances, long-term survival in liver transplant (LT) recipients is compromised by an increased risk of cardiovascular disease (CVD) after transplant, the mechanisms of wh...
Eligibility Criteria
Inclusion
- Aged \> 18 years
- Speak and understand English
- Have received and LT
Exclusion
- Acute cellular or chronic rejection within 3 months
- Post-LT liver or non-liver related malignancy
- Active viral hepatitis (B or C) or autoimmune hepatitis
- Untreated biliary strictures or vascular complications (e.g. hepatic artery thrombosis)
- Poorly controlled diabetes (HbA1c \>8.5%)
- Relapse of alcohol use after LT
- Follow a vegetarian or vegan diet
- Current pregnancy
- Unable to provide informed consent
Key Trial Info
Start Date :
January 18 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06043531
Start Date
January 18 2024
End Date
December 1 2025
Last Update
November 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia Commonwealth University
Richmond, Virginia, United States, 23298